High-Cost Medical Expenses Cap Raised
Effective August 1, 2026 (Phase 1). Monthly out-of-pocket cap raised 4–38% by income bracket. New annual cap of ¥530,000 for those earning ¥2–7.7M/year. Multiple-occurrence reduction kept as-is.
Effective April 1, 2026 — Choosing brand-name means paying 1/4 of the price gap
The "selected medical treatment" system for long-listed drugs is expanding with 34 new additions, totaling 775 items. When patients choose a brand-name drug over a generic equivalent, they must pay an extra 25% (1/4) of the price difference out of pocket.
Brand-name: ¥200/tablet, Generic: ¥80/tablet. Difference ¥120 × 1/4 = ¥30 extra. At 30% copay: normal ¥60 + extra ¥30 = ¥90 total.
Effective August 1, 2026 (Phase 1). Monthly out-of-pocket cap raised 4–38% by income bracket. New annual cap of ¥530,000 for those earning ¥2–7.7M/year. Multiple-occurrence reduction kept as-is.
From June 2026, new price-adjustment surcharges effectively raise initial consultation by ~¥20 and follow-up by ~¥30. Affects out-of-pocket costs for foreign residents at 30% copay.
From April 2026, drug prices cut by 0.86% (medical cost basis). Some items reduced by over 40% under market expansion reassessment. Lower out-of-pocket costs for foreign patients using prescription drugs.